The cumulative incidence of BRM at the 1-year time point for patients with HR-positive/ERBB2-negative cancer was 3.8% (95% CI, 2.8%-5.0%), ERBB2-positive/HR-positive cancer was 5.2% (95% CI, 3.1%-8.1%), ERBB2-positive/HR-negative cancer was 11.0% (95% CI, 7.1%-15.8%), and triple-negative MBC was 12.9% (95% CI, 9.1%-17.4%) (Figure). This evidence concerns the gene ERBB2 and cancer.